trending Market Intelligence /marketintelligence/en/news-insights/trending/mGKh0OCtBza2hh5byLjuGQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Patent protection challenge to delay Novartis' psoriasis biosimilar

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Patent protection challenge to delay Novartis' psoriasis biosimilar

The sale of Novartis AG's biosimilar copy of Amgen Inc.'s Enbrel will be delayed to 2018 due to a patent protection challenge in U.S. federal court, Reuters reported Jan. 25.

The U.S. FDA has already approved the biosimilar copy of Enbrel, called Erelzi, for rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and other diseases. But Amgen claims that the drug has patent protection until 2029.

Richard Francis, head of Novartis' Sandoz generics business, reportedly stated that the legal battle could take at least a year.